Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes

Journal of Controlled Release

Volumn 63, Issue 1-2, 2000, Pages 19-30

  Crosasso, Paola ^a   Ceruti, Maurizio ^a   Brusa, Paola ^a   Arpicco, Silvia ^a   Dosio, Franco ^a   Cattel, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Biodistribution; Liposomes; Paclitaxel; PEGylated liposomes; Pharmacokinetics

Indexed keywords

CREMOPHOR; LIPOSOME; PACLITAXEL;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; STEREOCHEMISTRY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHOLESTEROL; DRUG CARRIERS; FEMALE; HT29 CELLS; HUMANS; LIPOSOMES; MACROPHAGES; MICE; MICE, INBRED BALB C; PACLITAXEL; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; SUCCINIMIDES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0033964804     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00166-2     Document Type: Article

References (61)

1. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). N. Engl. J. Med. 332:1995;1004-1014.
2. Spencer C.M., Faulds D. Paclitaxel. Drugs. 48:1994;794-847.
3. Foa R., Norton L., Seidman A.D. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int. J. Clin. Lab. Res. 24:1994;6-14.
4. Horwitz S.B. Mechanism of action of taxol. Trends Pharmacol. Sci. 13:1992;134-136.
5. Chervinsky D.S., Brecher M.L., Hoelcle M.J. Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. J. Anticancer Res. 13:1993;93-96.
6. Webster L., Linsenmeyer M., Millward M., Morton C., Bishop J., Woodcock D. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. Natl. Cancer Inst. 85:1993;1685-1690.
7. Morgan A.R., Garbo G.M., Keck R.W., Selman S.H. New photosensitizers for photodynamic therapy: combined effect of metallopurpurin derivatives and light on transplantable bladder tumors. Cancer Res. 48:1988;194-198.
8. Fjallskog M.L., Frii L., Bergh J. Is cremophor, solvent for paclitaxel, cytotoxic? Lancet. 342:1993;876.
9. Rowinsky E.K., Eisenhauer E.A., Chaudry V., Arbuck S.G., Donehower R.C. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 20:1993;1-15.
10. Dorr R.T. Pharmacology and toxicology of Cremophor EL diluent. Ann. Pharmacother. 28:1994;S11-S14.
11. Goldspiel B.R. Pharmaceutical issues: preparation, administration, stability, and compatibility with other medications. Ann. Pharmacother. 28:1994;S23-S26.
12. Song D., Hsu L.F., Au J.L.S. Binding of taxol to plastic glass container and protein under in vitro conditions. J. Pharm. Sci. 85:1996;29-31.
13. Kongshaug M., Cheng L.S., Moan J., Rimington C. Interaction of cremophor EL with human plasma. J. Biochem. 23:1991;497-499.
14. Sykes E., Woodburn K., Decker D., Kessel D. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br. J. Cancer. 70:1994;401-404.
15. Nygren P., Csoka K., Jonsson B., Fridborg H., Bergh J., Hagberg H., Glimelius B., Brodin O., Tholander B., Kreuger A., Lönnerholm G., Jakobsson A., Olsen L., Kristensen J., Larsson R. The cytotoxic activity of taxol in primary cultures of tumor cells from patients is partly mediated by cremophor EL. Br. J. Cancer. 71:1995;478-481.
16. ®) in human cell lines. Cancer Chemother. Pharmacol. 33:1994;331-339.
17. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.L., Trump D., Baker J.R., VanEcho D.A., VonHoff D.D., Leyland-Jones B. Hypersensitivity reactions from taxol. J. Clin. Oncol. 8:1990;1263-1268.
18. Sharma U.S., Balasubramanian S.V., Straubinger R.M. Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins. J. Pharm. Sci. 84:1995;1223-1230.
19. Cserháti T., Holló J. Interaction of taxol and other anticancer drugs with hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 108:1994;69-75.
20. Cserháti T., Forgács E., Holló J. Interaction of taxol and other anticancer drugs with α-cyclodextrin. J. Pharm. Biomed. Anal. 13:1995;533-541.
21. Sharma A., Straubinger R.M. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm. Res. 11:1994;889-896.
22. Tarr B.D., Sambandan T.G., Yalkowsky S.H. A new parenteral emulsion for the administration of taxol. Pharm. Res. 4:1987;162-165.
23. Greenwald R.B., Gilbert C.W., Pendri A., Conover C.D., Xia J., Martinez A. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs - design and in vivo effectiveness. J. Med. Chem. 39:1996;424-431.
24. Nicolaou K.C., Guy R.K., Pitsinos E.N., Wrasidlo W. A water-soluble prodrug of taxol with self-assembling properties. Angew. Chem. Int. 33:1994;1583-1587.
25. Takahashi T., Tsukamoto H., Yamada H. Design and synthesis of a water-soluble taxol analogue: taxol-sialyl conjugate. Bioorg. Med. Chem. Lett. 8:1998;113-116.
26. Pendri A., Conover C.D., Greenwald R.B. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. Anti-Cancer Drug Des. 13:1998;387-395.
27. Burt H.M., Jackson J.K., Bains S.K., Liggins R.T., Oktaba A.M.C., Arsenault A.L., Hunter W.L. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (D,L-lactic acid). Cancer Lett. 88:1995;73-79.
28. Ramaswamy M., Zhang X., Burt H.M., Wasan K.M. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J. Pharm. Sci. 86:1997;460-464.
29. Dosio F., Brusa P., Crosasso P., Arpicco S., Cattel L. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J. Control. Release. 47:1997;293-304.
30. Kim S. Liposomes as carriers of cancer chemotherapy: current status and future prospects. Drugs. 46:1993;618-638.
31. Poste G. Liposomes targeting in vivo: problems and opportunities. Biol. Cell. 47:1983;19-38.
32. Sharma A., Sharma U.S. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154:1997;123-140.
33. Sharma A., Mayhew E., Straubinger R.M. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 53:1993;5877-5881.
34. Balasubramanian S.V., Straubinger R.M. Taxol-lipid interactions: taxol dependent effects on the physical properties of model membranes. Biochemistry. 33:1994;8941-8947.
35. Sharma A., Sharma U.S., Straubinger R.M. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett. 107:1996;265-272.
36. Sharma A., Mayhew E., Bolcsak L., Cavanaugh C., Harmon P., Janoff A., Bernacki R.J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer. 71:1997;103-107.
37. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipatic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:1990;235-237.
38. Maruyama K., Yuda T., Okamoto A., Kojima S., Suginaka A., Iwatsuru M. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim. Biophys. Acta. 1128:1992;44-49.
39. Allen T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharm. Sci. 15:1994;215-220.
40. Ceh B., Winterhalter M., Frederik P.M., Vallner J.J., Lasic D.D. Stealth liposomes: from theory to product. Adv. Drug Del. Rev. 24:1997;165-177.
41. Lasic D.D. Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo. J. Control. Release. 48:1997;203-222.
42. Gabizon A., Isacson R., Libson E., Kaufman B., Uziely B., Catane R., Ben-Dor C.G., Rabello E., Cass Y., Peretz T., Sulkes A., Chisin R., Berenholz Y. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 33:1994;779-786.
43. Unezaki S., Maruyama K., Ishida O., Suginaka A., Hosoda J., Iwatsuru M. Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipatic poly(ethylene glycol). Int. J. Pharm. 126:1995;41-48.
44. Daemen T., Regts J., Meesters M., Ten Kate M.T., Bakker-Woudenberg I.A.J.M., Scherphof G.L. Toxicity of doxorubicin entrapped within long-circulating liposomes. J. Control. Release. 44:1997;1-9.
45. Rouser G., Fleischer J., Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 5:1970;494-496.
46. Sharma A., Conway W.D., Straubinger R.M. Reversed-phase high-performance liquid chromatographic determination of taxol in mouse plasma. J. Chrom. B. 655:1994;315-319.
47. Crosasso P., Brusa P., Dosio F., Arpicco S., Cattel L. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. J. Pharm. Sci. 86:1997;832-839.
48. Brusa P., Dosio F., Pacchioni D., Delprino L., Grosa G., Bussolati G., Cattel L. Pharmacokinetics of an antibody-ricin conjugate administered intraperitoneally to mice. J. Pharm. Sci. 83:1993;514-519.
49. Sparreboom A., van Tellingen O., Nooijen W.J., Beijen J.H. Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. J. Chrom. 664:1995;383-391.
50. Wenk M.R., Fahr A., Resza R., Seelig J. Paclitaxel partitioning into lipid bilayers. J. Pharm. Sci. 85:1996;228-231.
51. Moyna G., Williams H.J., Scott A.I. Conformational studies of paclitaxel analogs modified at the C-2′ position in hydrophobic and hydrophilic solvent system. J. Med. Chem. 40:1997;3305-3311.
52. Mastropaolo D., Camerman A., Luo Y., Brayer G.D., Camerman N. Crystal and molecular structure of paclitaxel (taxol). Proc. Natl. Acad. Sci. USA. 92:1995;6920-6924.
53. Ventura C.A., Fresta M., Brusa P., Cattel L., Puglisi G. Taxol-cyclodextrin inclusion compounds as potential novel anticancer formulations. Proceedings 2nd World Meeting APGI/APV. 1998;727-728.
54. Maruyama K., Okuizumi S., Ishida O., Yamauchi H., Kikuchi H., Iwatsuru M. Phosphatidyl polyglycerols prolong liposome circulation in vivo. Int. J. Pharm. 111:1994;103-107.
55. Bedu-Addo F.K., Tang P., Xu Y., Huang L. Interaction of polyethyleneglycol-phospholipid conjugates with cholesterol-phosphatidylcholine mixtures: sterically stabilized liposomes formulations. Pharm. Res. 13:1996;718-724.
56. Bedu-Addo F.K., Tang P., Xu Y., Huang L. Effect of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: implication in liposomal drug delivery. Pharm. Res. 13:1996;710-717.
57. Bedu-Addo F.K., Huang L. Interaction of PEG-phospholipid conjugates with phospholipid: implication in liposomal drug delivery. Adv. Drug Del. Rev. 16:1995;235-247.
58. Mayhew E.G., Lasic D., Babbar S., Martin F.J. Pharmacokinetic and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int. J. Cancer. 51:1992;302-309.
59. Brenner D.E. Liposomal encapsulation: making old and new drug do new tricks. J. Natl. Cancer Inst. 81:1989;1436-1438.
60. Gabizon A., Goren D., Horowitz A.T., Tzemach D., Lossos A., Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Del. Rev. 24:1997;337-344.
61. Crosasso P., Brusa P., Dosio F., Arpicco S., Cattel L. Liposome containing paclitaxel and its hydrophilic prodrugs. Proc. Int. Symp. Control. Release Bioact. Mater. 25:1998;392-393.